Effect of cevimeline on salivary components in patients with Sjögren syndrome.
The aim of this study is to clarify the effects of cevimeline on various components in human saliva, such as immunoglobulin A (IgA), lysozyme, alpha-amylase and squamous cell carcinoma (SCC) antigen. Twelve female patients with Sjögren syndrome (SS) and 14 healthy women were enrolled. After the first saliva collection, one capsule (30 mg) of cevimeline was administered to each subject. Saliva was collected again after 90 min. The salivary flow rate and concentration of each component were measured. In both groups the salivary flow rate and amylase concentration were significantly increased by cevimeline. The lysozyme and IgA concentrations did not change significantly in both groups. The SCC antigen concentration did not change significantly in the SS group, but it decreased significantly in the control group. The secretion rates of amylase and IgA showed significant increases in both groups. The secretion rate of lysozyme significantly increased only in the control group, while the secretion rate of SCC significantly increased only in the SS group. Cevimeline augments not only the salivary flow rate but also the secretion rate of some digestive and/or defense factors from infections. It may be beneficial for SS patients to continue taking cevimeline to prevent oral infections, and other serious sequelae.
Suzuki
Kimihiro
K
Internal Medicine I, National Defense Medical College, Tokorozawa, Japan. kogen@me.ndmc.ac.jp
Matsumoto
Mitsuyo
M
Nakashima
Masahiro
M
Takada
Kunio
K
Nakanishi
Takashi
T
Okada
Makoto
M
Ohsuzu
Fumitaka
F
D000951:Antigens, Neoplasm / Q000032:analysis; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D008875:Middle Aged; D009113:Muramidase / Q000032:analysis; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D011812:Quinuclidines / Q000627:therapeutic use*; D012463:Saliva / Q000737:chemistry* / Q000378:metabolism; D012472:Salivation / Q000187:drug effects*; D015843:Serpins / Q000032:analysis; D012859:Sjogren's Syndrome / Q000150:complications* / Q000378:metabolism; D013876:Thiophenes / Q000627:therapeutic use*; D014987:Xerostomia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000516:alpha-Amylases / Q000032:analysis
D000951:Antigens, Neoplasm; D007070:Immunoglobulin A; D018721:Muscarinic Agonists; D011812:Quinuclidines; D015843:Serpins; D013876:Thiophenes; C051072:squamous cell carcinoma-related antigen; D000516:alpha-Amylases; D009113:Muramidase; C059240:cevimeline